NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,537.81 +223.95 (+1.22%) CRUDE OIL
79.33 +0.34 (+0.43%) GOLD FUTURES
2,341.60 +19.30 (+0.83%) DOW
39,352.43 +296.04 (+0.76%) Bitcoin GBP
49,538.05 -447.93 (-0.90%)
Achieve Life Sciences, Inc. (ACHV)
| Previous close | 4.7050 |
| Open | 4.7700 |
| Bid | 4.5900 x 100 |
| Ask | 4.6200 x 100 |
| Day's range | 4.5500 - 4.7800 |
| 52-week range | 3.0300 - 10.3000 |
| Volume | |
| Avg. volume | 106,700 |
| Market cap | 157.901M |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5000 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.75 |
GlobeNewswireAchieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events reported and excellent compliance to study treatment Achieve expects to conduct an End-of-Phase 2 Meeting with the FDA later this year to discuss Phase 3 trial plans SEATTLE and VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharm
- GlobeNewswire
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT. To access the webcast, please use the followi
- GlobeNewswire
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference
SEATTLE and VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2024 Conference being held at the Seattle Convention Center April 17-18, 2024. The Achieve corporate presenta
